The 2022-ICC retains a subgrouping for cases with MYC and BCL6 rearrangement; this is recognized as a heterogeneous category with variable gene expression profiles and mutational spectra [2]. The gene discussed is BCL6; the disease is intrahepatic cholangiocarcinoma.